Rheumatology Network's Top 5: April 30, 2021

April 30, 2021

Take 5 minutes to catch up on Rheumatology Network's highlights from the week ending April 30, 2021.

Plaque Psoriasis Treated With Secukinumab Not Affected by Comorbid Psoriatic Arthritis

Investigators observed that patients treated with secukinumab were more likely to achieve Psoriasis Area Severity Index (PASI) 75/90/100 responses and Investigator’s Global Assessment (IGA) improvement at 52 weeks than those administered usetkinumab, regardless of their psoriatic arthritis (PsA) status.

Click the image to view the story.

Philip J. Mease, MD: Guselkumab Efficacy for Psoriatic Arthritis

This week, Rheumatology Network sat down with Philip J. Mease, MD, to discuss his study, “Comparative effectiveness of guselkumab in psoriatic arthritis: results from systematic literature review and network meta-analysis.”

Click the image to view the story.

Neonatal Lupus Erythematosus Risk Not Linked to Ethnicity

“In this large, multiethnic, single-center, cohort study of children born to anti-Ro antibody positive mothers, the child’s ethnicity was not associated with NLE risk, nor specific NLE manifestations,” stated investigators.

Click the image to view the story.

Guselkumab May Improve Health-Related Quality of Life in Patients With Active Psoriatic Arthritis

“The sustained benefits for patients with active psoriatic arthritis across multiple domains indicate that guselkumab may offer a novel mechanism by which to provide extended improvements in the diverse manifestations of psoriatic arthritis,” Laura Coates, PhD, and team concluded.

Click the image to view the story.

SPIN-CHAT Program Reduces Anxiety and Depression Symptoms for Patients With Rheumatic Disease

The SPIN-CHAT Program was developed by investigators in order to help participants deal with isolation and learn better mental health coping mechanisms.

Click the image to view the story.